217 related articles for article (PubMed ID: 23665933)
1. CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with reduced CYP3A4 protein level and function in human liver microsomes.
Okubo M; Murayama N; Shimizu M; Shimada T; Guengerich FP; Yamazaki H
J Toxicol Sci; 2013; 38(3):349-54. PubMed ID: 23665933
[TBL] [Abstract][Full Text] [Related]
2. CYP3A5 Contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects.
Yamaori S; Yamazaki H; Iwano S; Kiyotani K; Matsumura K; Honda G; Nakagawa K; Ishizaki T; Kamataki T
Drug Metab Pharmacokinet; 2004 Apr; 19(2):120-9. PubMed ID: 15499178
[TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism.
Westlind-Johnsson A; Malmebo S; Johansson A; Otter C; Andersson TB; Johansson I; Edwards RJ; Boobis AR; Ingelman-Sundberg M
Drug Metab Dispos; 2003 Jun; 31(6):755-61. PubMed ID: 12756208
[TBL] [Abstract][Full Text] [Related]
4. Limited contribution of CYP3A5 to the hepatic 6beta-hydroxylation of testosterone.
Kamdem LK; Meineke I; Koch I; Zanger UM; Brockmöller J; Wojnowski L
Naunyn Schmiedebergs Arch Pharmacol; 2004 Jul; 370(1):71-7. PubMed ID: 15232676
[TBL] [Abstract][Full Text] [Related]
5. Evidence of significant contribution from CYP3A5 to hepatic drug metabolism.
Huang W; Lin YS; McConn DJ; Calamia JC; Totah RA; Isoherranen N; Glodowski M; Thummel KE
Drug Metab Dispos; 2004 Dec; 32(12):1434-45. PubMed ID: 15383492
[TBL] [Abstract][Full Text] [Related]
6. Genetic contribution to variable human CYP3A-mediated metabolism.
Lamba JK; Lin YS; Schuetz EG; Thummel KE
Adv Drug Deliv Rev; 2002 Nov; 54(10):1271-94. PubMed ID: 12406645
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the impact of CYP3A polymorphisms on the formation of α-hydroxytamoxifen and N-desmethyltamoxifen in human liver microsomes.
Mugundu GM; Sallans L; Guo Y; Shaughnessy EA; Desai PB
Drug Metab Dispos; 2012 Feb; 40(2):389-96. PubMed ID: 22096084
[TBL] [Abstract][Full Text] [Related]
8. Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily.
Gorski JC; Jones DR; Wrighton SA; Hall SD
Biochem Pharmacol; 1994 Jul; 48(1):173-82. PubMed ID: 8043020
[TBL] [Abstract][Full Text] [Related]
9. Role of a potent inhibitory monoclonal antibody to cytochrome P-450 3A4 in assessment of human drug metabolism.
Mei Q; Tang C; Assang C; Lin Y; Slaughter D; Rodrigues AD; Baillie TA; Rushmore TH; Shou M
J Pharmacol Exp Ther; 1999 Nov; 291(2):749-59. PubMed ID: 10525096
[TBL] [Abstract][Full Text] [Related]
10. Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs.
Walsky RL; Obach RS; Hyland R; Kang P; Zhou S; West M; Geoghegan KF; Helal CJ; Walker GS; Goosen TC; Zientek MA
Drug Metab Dispos; 2012 Sep; 40(9):1686-97. PubMed ID: 22645092
[TBL] [Abstract][Full Text] [Related]
11. Relative contributions of cytochrome CYP3A4 versus CYP3A5 for CYP3A-cleared drugs assessed in vitro using a CYP3A4-selective inactivator (CYP3cide).
Tseng E; Walsky RL; Luzietti RA; Harris JJ; Kosa RE; Goosen TC; Zientek MA; Obach RS
Drug Metab Dispos; 2014 Jul; 42(7):1163-73. PubMed ID: 24737844
[TBL] [Abstract][Full Text] [Related]
12. CYP3A4 * 1G Genetic Polymorphism Influences Metabolism of Fentanyl in Human Liver Microsomes in Chinese Patients.
Yuan JJ; Hou JK; Zhang W; Chang YZ; Li ZS; Wang ZY; Du YY; Ma XJ; Zhang LR; Kan QC; Candiotti KA
Pharmacology; 2015; 96(1-2):55-60. PubMed ID: 26088794
[TBL] [Abstract][Full Text] [Related]
13. Carbamazepine 10,11-epoxidation in human liver microsomes: influence of the
Miyata-Nozaka Y; Zain SM; Taguchi M; Shigeyama M; Isobe T; Hanioka N
Pharmazie; 2017 Dec; 72(12):747-750. PubMed ID: 29441960
[TBL] [Abstract][Full Text] [Related]
14. Factors influencing midazolam hydroxylation activity in human liver microsomes.
He P; Court MH; Greenblatt DJ; von Moltke LL
Drug Metab Dispos; 2006 Jul; 34(7):1198-207. PubMed ID: 16638818
[TBL] [Abstract][Full Text] [Related]
15. CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin.
Elens L; Nieuweboer A; Clarke SJ; Charles KA; de Graan AJ; Haufroid V; Mathijssen RH; van Schaik RH
Pharmacogenomics; 2013 Jan; 14(2):137-49. PubMed ID: 23327575
[TBL] [Abstract][Full Text] [Related]
16. Effects of cytochrome P450 2D6 and 3A5 genotypes and possible coadministered medicines on the metabolic clearance of antidepressant mirtazapine in Japanese patients.
Okubo M; Murayama N; Miura J; Chiba Y; Yamazaki H
Biochem Pharmacol; 2015 Jan; 93(1):104-9. PubMed ID: 25475885
[TBL] [Abstract][Full Text] [Related]
17. Individual differences in in vitro and in vivo metabolic clearances of antipsychotic risperidone from Japanese subjects genotyped for cytochrome P450 2D6 and 3A5.
Okubo M; Morita S; Murayama N; Akimoto Y; Goto A; Yamazaki H
Hum Psychopharmacol; 2016 Mar; 31(2):93-102. PubMed ID: 26856541
[TBL] [Abstract][Full Text] [Related]
18. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples.
Yamazaki H; Inoue K; Shaw PM; Checovich WJ; Guengerich FP; Shimada T
J Pharmacol Exp Ther; 1997 Nov; 283(2):434-42. PubMed ID: 9353355
[TBL] [Abstract][Full Text] [Related]
19. Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6.
Yumibe N; Huie K; Chen KJ; Snow M; Clement RP; Cayen MN
Biochem Pharmacol; 1996 Jan; 51(2):165-72. PubMed ID: 8615885
[TBL] [Abstract][Full Text] [Related]
20. Associations of the CYP3A5*3 and CYP3A4*1G polymorphisms with the pharmacokinetics of oral midazolam and the urinary 6β-hydroxycortisol/cortisol ratio as markers of CYP3A activity in healthy male Chinese.
Chan SW; Xiao Y; Hu M; Yin OQ; Chu TT; Fok BS; Lee VH; Tomlinson B
J Clin Pharm Ther; 2016 Oct; 41(5):552-8. PubMed ID: 27511886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]